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355 Metabolic alkalosis – clinical study of frequency, genotype–
phenotype correlation and treatment, on 60 patients from
Romania
S. Mosescu1. 1pediatrics, Clinical Central’s Children’s Hospital, Bucharest,
Romania
Metabolic alkalosis represents a frequent complication in cystic ﬁbrosis (CF), which
could become life threatening.
Aim of study: to establish the frequency of this complication in a group of 60
Romanian patients with CF, to correlate metabolic alkalosis with genotype, to
administrate the best treatment.
Methods: 60 patients with CF have been followed during 5 years to establish the
frequency of metabolic alkalosis (acute or chronic). For each one it was studied the
genotype divided in 3 subgroups: delta F508 homozygous, delta F508 heterozygous
compound, non delta F508. The treatment followed was: administration of sodium,
chloride and potassium for deﬁcit replacement, associated or not with arginine
monochloride infusion 10ml/kg/day, 3 consecutive days (arginine-sorbitol solution
5%).
Results: the frequency of metabolic alkalosis was 30% (18 patients) for the whole
group. We didn’t ﬁnd correlation with genotype, the frequency was: 30.4%, 30.4%,
28.6% for the 3 genotype subgroups. Administration of arginine monochloride
improves clinical status and haste the recovery of the biochemical parameters.
Conclusions: the frequency of metabolic alkalosis is 30% among patients with CF,
indifferently if the patient is homozygous delta F508, heterozygous delta F508, or
non delta F508. Association in the treatment of arginine monochloride improves
the evolution and it is mandatory in patients with severe degrees of alkalosis. Two
patients (5 years, 8 years old) with “IVS 8- 7T splice variant” had as the unique
clinical manifestation of CF, episodes of severe dehydration and metabolic acute
alkalosis.
356 An audit to identify the communication process of a diabetic oral
glucose tolerance test (OGTT) result to the patient before and
after the introduction of standards
R. Richmond1, D. McKenna1, M. Dodd1, A. Jones1. 1Adult CF Centre,
Wythenshawe Hospital, Manchester, United Kingdom
Introduction: Screening to identify CFRD early is important to prevent decline
prior to diagnosis. When screening is performed, it is important patients are
informed promptly of the result and appropriate action is taken. We audited the
communication of Diabetic OGTT results to patients prior to and following the
introduction of standards stating that the CF Nurse specialist (CFNS) would co-
ordinate and document feedback to patients within 4 weeks of the OGTT.
Aim: To assess if the introduction of standards improved the communication of
results to patients.
Method: Retrospective review of medical, diabetic nursing and dietetic notes to
identify in 2005 and post standards in 2007:
– Length of time before patients were informed of the result
– How patients were informed
– Who informed patients
Results: 12 patients had a diabetic OGTT in 2005 and 7 in 2007. In 2005 the length
of time before patients were informed varied – <1 month = 9 patients, 1−3 months =
2 patients, >3 months = 1 patient. In 2007 all patients were informed within 4 weeks.
Conclusion: The ﬁrst audit highlighted that no member of the CF team was
identiﬁed to co-ordinate the feedback of OGTT results. Poor communication of
the OGTT results within the CF team can lead to delayed feedback to patients.
Following the introduction of standards the second audit showed that the CFNS now
documents and informs all patients within 4 weeks, therefore meeting the standards
set.
Table 1: How patients were informed
Date Number of patients Who informed by
2005 2 Diabetologist – Ward
2005 6 CF Doctors – Ward
2005 4 Diabetologist – CFRD Clinic
2007 7 CFNS
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Introduction: Current UK guidelines recommend the use of an annual OGTT in
adult patients. Yung et al 19991 devised guidelines to determine which patients
should have an OGTT, and these have since been used in our unit. All patients are
invited for annual review (AR). They are screened at AR and more frequently if clin-
ically indicated. The decision for OGTT is based on random blood glucose (RBG)
11.1mmol/l; glycosylated haemoglobin (HbA1C) 6.1%; or clinical symptoms
(polydipsia, polyuria, nocturia, unexplained weight loss). If one or more of these
criteria are met, then an OGTT is performed.
Aim: To assess the validity of this selective approach.
Method: Patients with diabetes diagnosed from 2002 until 2006 were identiﬁed
from the departmental CF database. Patient demographics, place of diagnosis,
reason for OGTT, and blood results were recorded.
Results: 41 new diabetic patients (16F, 25M) were diagnosed at RBH between 2002
to 2006. 29 (70%) of whom had attended for AR. Of these 29, all met the above
criteria. 16 (55%) had isolated HbA1C6.1mmol/l; 2 (7%) had isolated RBG11;
6 (21%) had HbA1C6.1mmol/l and RBG 11; 4 (14%) had HbA1C6.1 and
clinical symptoms; and 1 (3%) had clinical symptoms only. 26 patients had
subsequent OGTT and 3 had capillary blood glucose monitoring (2 as inpatient
and 1 at home) for clinical and geographical reasons.
Conclusion: Using our selective approach over 5 years we did not miss the diagnosis
of diabetes in any patient. This approach is more time and cost effective than routine
annual OGTT.
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Introduction: Management of patients with an impaired glucose tolerance (IGT)
test result can be difﬁcult. The Oral glucose tolerance test (OGTT) should be
repeated in one years time or home blood glucose monitoring (HBGM) commenced
for those patients identiﬁed as showing signs of unexplained clinical deterioration.
However, this is an informal process. We audited the communication and documen-
tation of an IGT result to patients and the outcome following this.
Aim: To determine if patients with an IGT result in 2005 were informed of the
result and outcome of this.
Method: Retrospective review of medical, diabetic nursing and dietetic notes to:
– Identify patients with IGT and if they were informed of this.
– If HBGM was commenced and if so why.
– Outcome.
Results: 19 patients were identiﬁed. 14 of the 19 were informed, of these, 8
commenced HBGM. Poor documentation and communication within medical notes
and between multidisciplinary team members made it difﬁcult to identify the clinical
reasons why HBGM was commenced.
Following monitoring, 4 patients required no intervention, 1 was advised to make
dietary changes, 1 commenced oral hypoglycaemic agents and 2 commenced
insulin.
Conclusion: Given that some of the patients commenced treatment, the possibility
is raised that certain people requiring treatment are missed.
The audit identiﬁed the need for:
– Standards and a pathway to ensure that all patients are informed of the result.
– A member of the team to co-ordinate feedback of results to patients.
– A risk assessment tool to help identify clinical markers for the early detection of
Cystic Fibrosis Related Diabetes.
